Latest From BenevolentAI
As once-star investment funds fail, another major investor argues this is opportunity for UK biotech to demonstrate staying power.
New five-year deal shows convergence of big pharma and big tech continues – though both sectors are wary of hype surrounding AI and digital health.
PPF has bought a big stake in the UK-based T-cell specialist, one of many firms backed by investor Neil Woodford which have suffered stock slides in the past few months.
Having signed a multi-year, multi-target agreement with Lilly worth potentially $550m, Atomwise CEO Abe Heifets tells Scrip the burden of proof is on AI practitioners to start producing relevant and actionable data.
- Digital Health
- Therapeutic Areas
- Neurology, Nervous System
- Western Europe
- Parent & Subsidiaries
- Senior Management
Jackie Hunter, PhD, CEO
Brent Gutekunst, Chief Dev. Officer
Davy Suvee, VP, Product Mgmt.
Ivan Griffin, VP, Bus. Dev.
Patrick Keohane, MD, CMO
- Contact Info
Phone: 20 3096 0720
London, NW1 1LW
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.